The global Single-cell Analysis Market size is expected to reach USD 6.7 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.0% from 2021 to 2028. Expeditious technological advancements over the years have enabled a comprehensive analysis of transcriptome and genome in an individual cell.
Single-cell technology helps in assessing cellular heterogeneity and aids in the analysis of pathways and processes at the molecular level. This technology is evolving at a rapid pace with applications in oncology, immunology, and others. Moreover, the introduction of advanced devices that simplify transcriptomic and proteomics procedures is driving the market.
Advances in single-cell RNA sequencing (scRNAseq) allow researchers to thoroughly investigate unexplored rare cell types. The development of the microfluidics method has significantly broadened the implementation of single-cell genomic/transcriptomic analysis in the biomedical field. A substantial number of microfluidic devices have been modified for cell dissociation and tissue digestion.
The increasing number of research publications is representative of the increasing investment flow in R&D in this market. As the R&D activities are the base of innovation, these investments signify a healthy growth possibility for this market. Moreover, researchers are engaged in assessing spatial heterogeneity in gene expression profiles at a single cellular level; thus, are anticipated to boost the uptake of consumables and instruments for the analysis.
Related Press release @ Single-cell Analysis Market Report
Single-cell Analysis Market Report Highlights
- The consumables segment accounted for the largest revenue share due to the high adoption and demand of products offered under this segment
- Given the wide availability of different forms of reagents, this segment is responsible for constant revenue generation
- Owing to the high-end features and the technically advanced analytical options, automated instruments contributed to maximum revenue share
- The oncology segment is majorly benefited by the advancements in single-cell analysis methods
- To avoid risks associated with cancer therapy, single-cell analysis techniques are being heavily adopted for cancer genomics
- There is increasing demand for prenatal diagnosis and non-invasive techniques for the detection of single-gene disorders associated with the fetus
- This has increased the adoption of single-cell analysis for prenatal diagnosis
- Single-cell analysis is being widely employed by various end-users, ranging from academic research institutes to biotechnology and pharmaceutical companies
- Academic and research institutes held a significant share due to wide usage across various studies
- North America dominated the 2020 global market owing to the increasing R&D of robust therapies and disease diagnosis
- Asia-Pacific is projected to witness the fastest CAGR, with India and China at the forefront
- Thermo Fisher Scientific, QIAGEN NV, Illumina Inc., Merck Millipore, BGI, Fluidigm Corporation, and Bio-Rad Laboratories are some prominent entities in this space.
- Companies have focused on the development of new innovative products to gain a competitive advantage
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment